

## DAFTAR PUSTAKA

1. Li L, Xia Y, Chen C, et al. Neutrophil-lymphocyte ratio in systemic lupus erythematosus disease: a retrospective study. *Int J Clin Exp Med* 2015;8(7):11026-11031.
2. Soliman WM, Sherif NM, Ghanima IM, et al. Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erytematosus: Relation with Disease Activity and Lupus Nephritis. *Reumatol Clin.* 2018;1-7 doi: 10.1016/j.reuma.2018.07.008
3. Bertsias G, Cervera R, Boumpas DT. Systemic lupus erythematosus: pathogenesis and clinical features. EULAR Text Book on Rheumatic Disease. 2012;20:476-505.
4. Dachenko N, Satia JA, Anthony MS. Epidemiology of Systemic Lupus Erhythematosus: a Comparison of World Wide Disease Burden. *Lupus.* 2006;15(5):308-318.
5. Perhimpunan Reumatologi Indonesia. Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sitemik. 2019;1-113.
6. Kaplan MJ. Role of neutrophils in systemic autoimmune disease. *Kaplan Arthritis Research & Therapy.* 2013;15:219
7. Bosch X. Systemic Lupus Erythematosus and the Neutrophil. *N ENGL J MED.* 2011;365;8
8. Linge P, Fortin PR, Lood C, et.al. The non-haemostatic role of platelet in systemic lupus erythematosus. *Nature Review Rheumatology.* 2018;14:195-213.
9. Kaplan, MJ. Neutrophils in the pathogenesis and manifestations of SLE. *Nat Rev Rheumatol.* 2012; 7(12):691-699.
10. Wu Y, Chen Y, Yang X, et al. Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. *International Immunopharmacology.* 36(2016) 94-99.
11. Lee YH, Song GG. Association of Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Mean Platelet Volume with Systemic Lupus Erythematosus Disease Activity: A Meta-analysis. *J Rheum Dis.* 2017; 24:10:279-286.
12. Suarjana IN. Imunopatogenesis Lupus Eritematosus Sistemik. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, et al, editor. Ilmu Penyakit Dalam Jilid III. Edisi keenam. Jakarta: Interna Publishing. 2009;3331-3345.
13. Freire EAM, Souto LM, Ciconelli RM. Assesment measures in systemic lupus erhytematosus. *Rev Bras Reumato.* 2011;51(1):70-80.
14. Suntoko B. Gambaran Klinik dan Diagnosis Lupus Eritematosus Sistemik. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, et al, editor. Ilmu Penyakit Dalam Jilid III. Edisi keenam. Jakarta: Interna Publishing. 2009;3351-3357.

15. Hahn BH. Systemic Lupus Erythematosus. In : Kasper DL, Hauser, SL, Jameson JL, et al, editor. Harrison's Principles od Internal Medicine. 19th edition. New York: mcGraw-Hill Education. 2015;2124-2134.
16. Sequeira JF, Keser G, Greenstein B, et al. Systemic lupus erythematosus: sex hormones in male patients. *Lupus* 1993;2:315–317.
17. Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. *Lupus* 2000;9:252–257.
18. McMurry RW, May W (2003) Sex hormones and systemic lupus erythematosus. *Arthritis Rheum*. 2003;48:2100-2110.
19. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human peripheral blood mononuclear cells. *J Allergy Clin Immunol*. 1999;103:282–8.
20. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. *Arthritis Rheum*. 1999;42:328–37 .
21. Mok CC, Lau CS. Pathogenesis of systemic lupus erithematosus. *J Clin Pathol*. 2003;56:481–490.
22. D'Cruz D, Espinoza G, Cervera R. Systemic lupus erythematosus: pathogenesis, clinical manifestations, and diagnosis. 2010 [cited 2018 Aug 9]. Available from:[http://www.eular.org/myuploaddata/files/Compendium\\_sample\\_chapter.pdf](http://www.eular.org/myuploaddata/files/Compendium_sample_chapter.pdf)
23. Petri M, Orbai A-M, et al, Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012; 64:2677-2686
24. Uribe AG, Vila LM, McGwin G, et al. The systemic lupus activity measure-revised, the mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. *The Jof Rheum*. 2004; 31(10);1934-1940.
25. Leiding JW. Neutrophil Evolution and Their Diseases in Humans. *Frontier in Immunology*. 2017;8;1-8
26. Rosales, Carlos. “Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?.” *Frontiers in physiology* vol. 9 113. 20 Feb. 2018, doi:10.3389/fphys.2018.00113
27. Yap, Desmond Y H, and Tak Mao Chan. “B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.” *International journal of molecular sciences* vol. 20,24 6231. 10 Dec. 2019, doi:10.3390/ijms20246231
28. Van Gorkom, Gwendolyn N Y et al. “Influence of Vitamin C on Lymphocytes: An Overview.” *Antioxidants (Basel, Switzerland)* vol. 7,3 41. 10 Mar. 2018, doi:10.3390/antiox7030041
29. Chen W, Lin J. Lymphopenia relating to T-lymphocyte apoptosis in systemic lupus erythematosus. *Clin Rheumatol*. 2011;30:1515–16.

30. Silva LM, Garcia AB, Donadi EA. Increased lymphocyte death by neglect-apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. *J Neurol*. 2002;249:1048–54.
31. Musai M. Terapi lupus eritematosus sistemik dengan penghambatan kostimulasi sel T. *Maj Kedokt Indon*. 2010;60(10):474-9.
32. Cohen PL. T- and B-cell abnormalites in systemic lupus. *J Invest Dermatol*. 1993;100:69S–72S.
33. Ghoshal, Kakali, and Maitree Bhattacharyya. “Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis.” *TheScientificWorldJournal* vol. 2014 781857. 3 Mar. 2014, doi:10.1155/2014/781857
34. B. Qin, et al., Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients, *Mod. Rheumatol*. 26 (3) (2016) 372–376.
35. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy*. 2001; 102: 5-14.
36. A.U. Uslu, et al., Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio, *Int. J. Rheum. Dis.* (2015).
37. L. Ma, et.al., Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with systemic lupus erythematosus and their correlation with activity: A meta-analysis, *International Immunopharmacology* 76 (2019) 105949
38. Fu. H, et.al, Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. *Clin Lab*. 2015;61(3-4):269-73. doi: 10.7754/clin.lab.2014.140927.
39. Erre, GL, et.al. Meta-analysis of neutrophil-to lymphocyte and platelet-to lymphocyte ratio in rheumatoid arthritis. *Eur J Clin Invest*. 2019;49:e13037. DOI: 10.1111/eci.13037
40. Kim, DS, et.al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. *J Dermatol*. 2016 Mar;43(3):305-10. doi: 10.1111/1346-8138.13061
41. Asahina. A, et.al. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriatic and psoriatic arthritis: Response to therapy with biologics. *J Dermatol*. 2017 Oct;44(10):1112-1121. doi: 10.1111/1346-8138.13875



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN KESEHATAN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR



Sekretariat : Lantai 3 Gedung Laboratorium Terpadu

JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK Telp. 091241050050, 0411 5780103, Fax: 0411-581431

**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 336/UN4.6.4.5.31/PP36/2020

Tanggal: 25 Juni 2020

Dengan Ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH19121150	No Sponsor Protokol	
Peneliti Utama	<b>dr Ismunandar</b>	Sponsor	
Judul Peneliti	Hubungan Rasio Netrofil Limfosit dan Rasio Platelet Limfosit Dengan Aktivitas Penyakit Pada Pasien Lupus Eritematosus Sistemik		
No Versi Protokol	2	Tanggal Versi	<b>12 Mei 2020</b>
No Versi PSP	2	Tanggal Versi	<b>12 Mei 2020</b>
Tempat Penelitian	<b>RSUP Dr Wahidin Sudirohusodo Makassar, RSPTN Universitas Hasanuddin , RS Ibnu Sina , RS Islam Faisal, RS Akademis Jaury dan Klinik Reumatik Makassar</b>		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard	Masa Berlaku <b>25 Juni 2020</b> Sampai <b>25 Juni 2021</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FK UH	Nama <b>Prof.Dr.dr.Suryani As'ad.,MSc,Sp.GK (K)</b>	Tanda tangan 	Tanggal
Sekretaris Komisi Etik Penelitian Kesehatan FK UH	Nama <b>dr. Agussalim Bukhari, M.Med, PhD, Sp.GK (K)</b>	Tanda tangan 	Tanggal

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan